Monitoring tuberculosis progression using MRI and stereology
|
|
- Vivien Jordan
- 5 years ago
- Views:
Transcription
1 Monitoring tuberculosis progression using MRI and stereology
2 TB the problem Estimated number of new cases in million deaths; 9 million new cases p.a. TB kills someone every 15 secs, 9,153 cases in UK (2009), Latent infection (one third of world s population) Co-infection with HIV, drug resistance (MDR, XDR)
3 Mycobacterium tuberculosis - antibiotic therapy Drug sensitive strains: 6+ months therapy: 2-4 antibiotics 5k Drug resistant strains: 18+ months therapy: 5+ antibiotics 50-70k UK = 70 million pa Issues: - non-compliance - side-effects Increasing numbers of MDR / XDR strains
4 Mycobacterium tuberculosis - vaccination BCG vaccine M. bovis [bacille Calmette Guerin]: live, attenuated inexpensive, safe, 3 billion doses effective in children - not adults variable efficacy globally [0-80%] live vaccine not recommended for babies with HIV does not prevent infection [latency]
5 Background The global needs: Therapy - new drug targets - shorter treatment times Vaccines - improve BCG / boost BCG (sub-unit vaccine) - NO CURRENT CORRELATE OF PROTECTION In vivo Models - Well characterised - Predictive - Clear readouts
6 Animal models of M. tuberculosis infection Rational approach to model development and use Three species predominantly used for efficacy studies Vaccines SUSCEPTIBILITY move through TO INFECTION progressively WITH more M. tuberculosis complex models prior to clinical trial Clinical Trials - Immunogenicity, mechanisms of action - Protection against Mtb challenge - Protection against Mtb challenge, - more stringent & discriminative - Detailed and relevant immunogenicity - Safety - Protection against Mtb challenge
7 Macaque models for TB vaccine evaluation 2 species are commonly used to model human tuberculosis Rhesus macaque Cynomolgus macaque Macaca mulatta mulatta: Indian and Chinese subspecies Macaca fascicularis: Native: e.g. S.E. Asia, Philippines. Introduced alien species: e.g. Mauritius. History : Rhesus macaque; aerosol / intra-bronchial challenge; BCG effective 1996 to date: Cynomolgus macaque: intra-tracheal challenge 2001: Langermans et al: BCG protective in cynomolgus, partially protective in rhesus. Lack of clear criteria for species selection for the evaluation of therapeutic interventions against tuberculosis. Need for further studies to: Characterise the species and the model for different uses. Define and improve study endpoints and readouts.
8 Aims To establish aerosol challenge models of TB infection in NHP To characterise and compare rhesus and cynomolgus macaque species as models of human tuberculosis for vaccine assessment. Susceptibility to infection with M. tuberculosis Similarity to humans To evaluate readouts of vaccine immunogenicity and efficacy including the evaluation of advanced imaging approaches to enhance measurement of disease burden
9 Aims To establish aerosol challenge models of TB infection in NHP To characterise and compare rhesus and cynomolgus macaque species as models of human tuberculosis for vaccine assessment. Susceptibility to infection with M. tuberculosis Similarity to humans To evaluate readouts of vaccine immunogenicity and efficacy including the evaluation of advanced imaging approaches to enhance measurement of disease burden
10 Aerosol Challenge Model Clinical parameters Humane endpoint indicators Behavioural indicators Depressed or withdrawn behaviour, Abnormal respiratory rates (dyspnoea). Weight Loss of 20% of peak post-challenge weight. Temperature Increased temperature Measures of inflammation Erythrocyte Sedimentation Rate ESR levels > normal Chest X-ray Severely abnormal chest X-ray Haematology: Full blood count (CBC) Hb Haemoglobin level < normal limits X-radiograph
11 Incubation (Days). Incubation (days). Incubation (days). Incubation (days). Aerosol Challenge Model Assessment of the Immune response Identification of correlates of protection, disease pathogenesis - Time course studies Immune responses investigated: Cytokine IFN-γ model calibrator; ELISPOT, ELISA, ICS Cellular responses: e.g. Polyfunctional T cells, proliferation Mucosal responses: BAL, lung Humoral responses Omics Mean Conc pg/ml IFNg Mean Conc pg/ml Mucosal MVA85A vaccination group Intradermal MVA85A vaccination group TNFa. Mucosal T-cell profile (BAL) Peripheral T-cell profile (PBMC) ELISpot method Aligned with human clinical trials ELISpot method ELISPOT ELISPOT: measures Frequency the IFN-γ Frequency secreting of cells specific cells ELISA: which Quantity secrete of IFN-γ secreted Anti-IFNgamma Cells IFN- γ Detection complex coating antibody (mononuclear Anti-IFNgamma cells (biotinylated Cells detector IFN- antibody, γ Detection complex isolated coating from antibody blood or lymphoid tissue) (mononuclear Streptavidin-ALP cells isolated and from BCIP/NBT blood substrate) (biotinylated detector antibody, Streptavidin-ALP or lymphoid tissue) and BCIP/NBT substrate) ELISA measures the Quantity of IFN-γ s PPD-specific IFN-gamma producing cells/10 6 PBMC 100μl 100μl 500 1:5 diluted blood Antigen solution Rhesus medians (n=12) Human median values (n=8) days at 37 o C Supernatants stored at 80 o C pre Weeks post-bcg IFN-gamma vaccination ELISA assay Mean Conc pg/ml. IL-2 IL Mean Conc pg/ml
12 Aerosol Challenge Model Assessment of disease at necropsy Pathology / Histology Scoring system for TB NHP disease pathology (qualitative) Pulmonary disease Pathology score Manual lesion count H&E for evaluation of lesion pathology Bacteriology Organ-specific bacterial load Evaluation of imaging for determination of pulmonary disease Visualisation of disease Quantification of disease (lesion counting; lesion : lung volume by stereology)
13 Aerosol Challenge Model development VACCINE EVALUATION AEROSOL CHALLENGE DOSE ESTABLISHED READOUTS OF DISEASE BURDEN ESTABLISHED IMMUNE ASSAYS ESTABLISHED ALIGNED HUMAN CLINICAL TRIALS HUMANE ENDPOINT CRITERIA ESTABLISHED X-RAY CAPABILITY HOUSING SYSTEM - CL3 CONTAIMENT AEROSOL DELIVERY SYSTEM: NHP PLETHYSMOGRAPHY
14 Readouts of disease burden for evaluation of TB vaccine efficacy Vaccine evaluation studies require readouts capable of demonstrating that vaccine candidates are able to protect against challenge with tuberculosis. The ideal readout would be Discriminatory Sensitive Objective Quantitative Transferable
15 % survival Readouts of disease burden for evaluation of TB vaccine efficacy Current readouts Survival: Long term studies required, larger numbers. Clinical assessment: X-ray: Qualitative, not easily transferable. Gross pathology: Qualitative, not easily transferable. Bacterial load in tissues: Technically challenging. Test groups with survivors and non survivors show a large variation in group bacterial load. D53: Pre exposure D53: 4 weeks post exposure to Mtb Immune responses: No correlate of protection Survival time post-challenge Time post-challenge (days) BCG prime, MVA85 boost (id) BCG prime, MVA85 boost (in) BCG prime, Ad85 boost (in) BCG prime, Rv3407 boost BCG::2F9 EsxA- His BCG Danish Saline Viable M. tuberculosis Log10 CFU/ml Lung Spleen < <0.001 BCG Danish (1331) s.c Lipid Pk negative control BCG Moreau oral BCG Danish Lipid Pk oral BCG Moreau Lipid Pk oral Viable M. tuberculosis Log 10 CFU/ml BCG Danish (1331) s.c Lipid Pk negative control BCG Moreau oral BCG Danish Lipid Pk oral BCG Moreau Lipid Pk oral Survival Clinical assessment Bacterial load
16 Improved readouts - Advanced Medical Imaging Imaging systems Computed tomography (CT) uses X-rays to construct good high resolution 3D images of tissue. Shorter scan time, less detailed images, bone imaging possible Magnetic resonance imaging (MRI) uses strong magnetic fields and nonionising radiation to generate high contrast 3D images Longer scan time, high resolution images, multiple scan types, not calcification MR Imaging of TB infected lungs performed ex-vivo Lungs inflated with formalin, embedded in agarose Contained samples transported to Oxford for scanning (MR, CT) Visualisation of disease burden Quantification of disease burden CT - MR stereology Total lung and lesion volumes determined from MR digital image stacks Lesion : lung volume ratio determined as measure of disease burden
17 Imaging based readouts of disease burden Visualisation of pulmonary disease: Pathology Rhesus macaques Dose M. tuberculosis High: 75 CFU Mid: 45 CFU Low: 30 CFU Pulmonary disease induced following aerosol exposure. Increased level of disease burden with increased exposure dose of M. tuberculosis.
18 Imaging based readouts of disease burden Visualisation of pulmonary disease: MR Images Rhesus macaques Dose M. tuberculosis 75 CFU 40 CFU 30 CFU Even distribution of disease following aerosol exposure. Clearly shows the increased level of disease burden with increased exposure dose of M. tuberculosis.
19 Imaging based readouts of disease burden Visualisation of pulmonary disease: MR Images Rhesus Mauritian Chinese Cynomolgus Cynomolgus Increased level of disease burden in Rhesus and Mauritian cynomolgus macaques compared to Chinese Cynomolgus macaque
20 Total lesion count Imaging based readouts of disease burden Quantification of pulmonary disease Study 2.1: Comparison of total lung lesion counts obtained from MRI scans and Lesion by slicing and counts manual counting Order of challenge Rhesus macaques CT MR Manual Lesions enumerated from Cross sectional CT or MR images Sliced lung sections Number of lesions D53 D31 D80 Dose M. tuberculosis CFU X-ray Score Excellent correlation of CT, MR, with pathology counts. Counting provides an over all view of disease burden Limitations at high levels of disease Lesion size not included
21 Lesion : lung volume Imaging based readouts of disease burden Quantification of pulmonary disease Lesion volume : Lung volume [MR stereology] Sharpe et al., Tuberculosis 0.4 Rhesus macaques Rhesus macaques D53 D12 D19 D28 D42 C54 D60 D80 D31 Dose Dose M. tuberculosis CFU The lesion to lung ratio is an indicator of disease severity, the higher the ratio the greater the proportion of lung is taken up with lesions. ratio
22 M. tuberculosis infection studies Disease burden measures: 0.4 lesion volume: lung volume ratio (MRI) Rhesus macaques 0.3 Quantitative measures Lesion volume / Lung volume ratio Lesion: lung volume Lesion count Number in lung Total lung lesion count D53 D12 D19 D28 D42 C54 D60 D80 D31 Qualitative measures Lung gross path score Total gross path score Score Score Lung pathology score Total pathology score D53 D12 D19 D28 D42 C54 D60 D80 D31 D53: Pre exposure D53: 4 weeks post exposure to Mtb Blue fill indicates animals which met humane endpoint before week 12 Lesion : lung volume ratio correlates with the other measures of pulmonary disease assessed Chest X-ray score Score Chest X ray Score D53 D12 D19 D28 D42 C54 D60 D80 D31 Mtb Challenge to euthanise interval (weeks) Quantitative data was more sensitive than the Qualitative measures of pulmonary disease (gross pathology score, Chest X-ray score).
23 Lesion : lung volume Lesion volume : Lung volume [MR stereology] Vaccine efficacy readout Sharpe et al., Clinical & vaccine Immunology 0.4 Unvaccinated 0.4 BCG vaccinated k54 K47 K62 K K44 K52 K80 K43 K50 K59 Grey fills indicates animals which did not met humane endpoint before end of study (week 52) A significant difference lesion volume to lung volume ratio was seen between the unvaccinated animals and animals vaccinated with BCG alone (p = 0.011)
24 In life imaging Use of mobile scanner units MR: Abdomen apex to base CT: Head to base
25 In life imaging at HPA Porton CT imaging with software reconstruction CT: voyage down the trachea Bronchoscopy: Trachea
26 Summary Visualisation of pulmonary disease - MR imaging provided a clear indication of pulmonary disease burden in fixed tissues. Quantification of disease burden: Lesion counting - Provided an overall view of pulmonary disease burden, but didn t take lesion size into account. - Agreement between lesion counts from CT or MR images with counts from pathological specimens validates the approach for use in life. MR stereology (lesion volume to lung volume ratio) - Provides a tool to quantify pulmonary disease induced by M. tuberculosis infection. - Superior to qualitative readouts of disease burden. - Provides a reliable measure against which to validate the Immunological correlates of vaccine-induced protective efficacy.
27 Future - Imaging Inclusion of imaging in future studies Application of stereology approach to CT image stacks In life imaging Development of a suitable containment strategy Evaluation of MR and CT modalities Evaluation of PET CT
The non-human primate model in TB vaccine development
April 10, 2015 The non-human primate model in TB vaccine development Tom Evans MD Aeras Agenda Issues Transmission studies Recent advancements Outcomes Endpoint analysis Design Going forward 2 Development
More informationPerspective in novel TB vaccine development Mohamed Ridha BARBOUCHE M.D., Ph.D. Department of Immunology Institut Pasteur de Tunis
Perspective in novel TB vaccine development Mohamed Ridha BARBOUCHE M.D., Ph.D. Department of Immunology Institut Pasteur de Tunis Existing TB Vaccine is not effective for global TB epidemic control BCG
More informationSummary of Key Points WHO Position Paper on BCG Vaccine, February 2018
Summary of Key Points WHO Position Paper on BCG Vaccine, February 2018 1 Introduction This position paper replaces the 2004 WHO position paper on Bacille Calmette-Guérin (BCG) vaccine and the 2007 WHO
More informationUpdate on TB Vaccines. Mark Hatherill South African TB Vaccine Initiative (SATVI) University of Cape Town
Update on TB Vaccines Mark Hatherill South African TB Vaccine Initiative (SATVI) University of Cape Town 1 Robert Koch s Therapeutic TB vaccine 1890: Purified Tuberculin Protein 1891: First negative reports
More informationGlobal progress in vaccine development
Global progress in vaccine development Helen McShane The Jenner Institute University of Oxford helen.mcshane@ndm.ox.ac.uk Vaccination The most cost-effective health intervention Smallpox Poliomyelitis
More informationA Multicistronic DNA Vaccine Induces Significant Protection against Tuberculosis in Mice and Offers Flexibility in the Expressed Antigen Repertoire.
Company LOGO A Multicistronic DNA Vaccine Induces Significant Protection against Tuberculosis in Mice and Offers Flexibility in the Expressed Antigen Repertoire. Fayaz Ahmad Mir, Stefan H. E. Kaufmann,
More informationTB Intensive Tyler, Texas December 2-4, 2008
TB Intensive Tyler, Texas December 2-4, 2008 Interferon Gamma Releasing Assays: Diagnosing TB in the 21 st Century Peter Barnes, MD December 2, 2008 TOPICS Use of interferon-gamma release assays (IGRAs)
More informationTB Intensive San Antonio, Texas November 11 14, 2014
TB Intensive San Antonio, Texas November 11 14, 2014 Interferon Gamma Release Assays Lisa Armitige, MD, PhD November 12, 2014 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of
More informationUpdate on TB Vaccines
Update on TB Vaccines Hennie Geldenhuys 11 May 2012 A safe and effective TB Vaccine within a decade A Strategic Blueprint for the Next Decade Tuberculosis, Vol 92, March 2012, Suppl. 1, pgs S1-S35 On
More informationCommunicable Disease Control Manual Chapter 4: Tuberculosis
Provincial TB Services 655 West 12th Avenue Vancouver, BC V5Z 4R4 www.bccdc.ca Communicable Disease Control Manual Definitions Page 1 2.0 DEFINITIONS Many of the definitions that follow are taken from
More informationPRIMAGAM - The primate IFN-ү test
PRIMAGAM - The primate IFN-ү test B. Schroeder {Prionics AG, Schlieren, Switzerland} Correspondence to: Bjoern.Schroeder@prionics.com 1 1 1 1 1 0 1 1 Introduction On December nd 0, Prionics gave a presentation
More informationPhilana Ling Lin,, JoAnne L. Flynn, Peter Andersen
The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection Philana Ling Lin,, JoAnne
More informationCHAPTER 3: DEFINITION OF TERMS
CHAPTER 3: DEFINITION OF TERMS NOTE: TB bacteria is used in place of Mycobacterium tuberculosis and Mycobacterium tuberculosis complex in most of the definitions presented here. 3.1 Acid-fast bacteria
More informationTB Nurse Case Management San Antonio, Texas July 18 20, 2012
TB Nurse Case Management San Antonio, Texas July 18 20, 2012 IGRA s and Their Use in TB Nurse NCM Lisa Armitige, MD, PhD July 18, 2012 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict
More informationMycobacterial Infections: What the Primary Provider Should Know about Tuberculosis
Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Epidemiology Diagnosis of active TB Screening
More informationTB Intensive Houston, Texas October 15-17, 2013
TB Intensive Houston, Texas October 15-17, 2013 Interferon Gamma Release Assays (IGRA s) Lisa Armitige, MD, PhD October 16, 2013 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict
More informationTB vaccine progress. Hassan Mahomed. Institute of Infectious Disease and Molecular Medicine, School of Child and Adolescent Health,
TB vaccine progress Hassan Mahomed South African TB Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine, School of Child and Adolescent Health, University of Cape Town, South
More informationUpdate on Tuberculosis Vaccines
March 27, 2014 Update on Tuberculosis Vaccines - 2014 Tom Evans MD CEO, Aeras TB is Mother Nature s AERAS GLOBAL number TB VACCINE one FOUNDATION killer over the past centuries TB is spread through the
More informationRUTI: a new therapeutic vaccine to shorten the latent tuberculosis infection treatment
RUTI: a new therapeutic vaccine to shorten the latent tuberculosis infection treatment Authors: Cristina Vilaplana, Sergio Pinto, Eva Montané, Mahavir Singh, Vicenç Ausina, Joan Costa, Pere-Joan Cardona
More informationNew Tuberculosis Vaccines Developmental Strategies
New Tuberculosis Vaccines Developmental Strategies Michael Brennan, Ph.D. Aeras SAGE Geneva, Switzerland 10 November 2011 The Potential of New TB Vaccines A new, more effective TB vaccine could: Be safer
More informationEvaluation of Mycobacterium tuberculosis specific T cell response to ESAT-6 and PPD antigen with ELISPOT assay
In the name of God Evaluation of Mycobacterium tuberculosis specific T cell response to ESAT-6 and PPD antigen with ELISPOT assay presented by: M. Taheri Symptoms of TB Cough for more than two week Bloody
More informationExosomes function in antigen presentation during an in vivo Mycobacterium tuberculosis infection
Exosomes function in antigen presentation during an in vivo Mycobacterium tuberculosis infection Victoria L. Smith, Yong Cheng, Barry R. Bryant and Jeffrey S. Schorey Supplementary Figure 1: Unprocessed
More informationTuberculosis. New TB diagnostics. New drugs.new vaccines. Dr: Hussein M. Jumaah CABM Mosul College of Medicine 23/12/2012
Tuberculosis New TB diagnostics. New drugs.new vaccines Dr: Hussein M. Jumaah CABM Mosul College of Medicine 23/12/2012 Tuberculosis (TB )is a bacterial disease caused by Mycobacterium tuberculosis (occasionally
More informationFostering Clinical Development for HIV-1 Vaccine
W Fostering Clinical Development for HIV-1 Vaccine Ravimiarenduse alane seminar 9. oktoobril Tallinnas Mart Ustav, PhD CSO, SVP 1 FIT Biotech Founded in 1995 Operations in Tampere, Finland and Tartu, Estonia
More informationstaining and flow cytometry
Detection of influenza virus-specific T cell responses by intracellular by cytokine intracellular staining cytokine staining and flow cytometry Detection of influenza virus-specific T cell responses and
More informationApproaches to LTBI Diagnosis
Approaches to LTBI Diagnosis Focus on LTBI October 8 th, 2018 Michelle Haas, M.D. Associate Director Denver Metro Tuberculosis Program Denver Public Health DISCLOSURES I have no disclosures or conflicts
More informationEvaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014
Evaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014 Interferon Gamma Release Assays: Understanding the Test David Griffith, BA, MD April 11, 2014 David Griffith, BA, MD has the following
More informationGap identification as a critical step to enable integrated clinical trial simulation platforms
Gap identification as a critical step to enable integrated clinical trial simulation platforms Application to TB Eline van Maanen Joost de Jongh Peter Vis September 26, 2013 LEIDEN EXPERTS ON ADVANCED
More informationPeggy Leslie-Smith, RN
Peggy Leslie-Smith, RN EMPLOYEE HEALTH DIRECTOR - AVERA TRAINING CONTENT 1. South Dakota Regulations 2. Iowa Regulations 3. Minnesota Regulations 4. Interferon Gamma Release Assay (IGRA)Testing 1 SOUTH
More informationTB Epidemiology. Richard E. Chaisson, MD Johns Hopkins University Center for Tuberculosis Research
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationPrevalence of tuberculosis (TB) infection and disease among adolescents western Kenya: preparation for future TB vaccine trials
Prevalence of tuberculosis (TB) infection and disease among adolescents western Kenya: preparation for future TB vaccine trials Videlis Nduba 1,2, Peter Onyango 1, Anja Van t Hoog 1,3, Anthony Hawkridge
More informationOsteomyelitis Caused by Bacille Calmette-Gu (BCG) Vaccination: 2 Cases
Osteomyelitis Caused by Bacille Calmette-Gu Guérin (BCG) Vaccination: 2 Cases Yoo, WonJoon Seoul National University Children s Hospital Seoul, Korea CASE 1 M / 11mos Pain & LOM, Knee, Rt. Swelling at
More informationFinal published version:
Boosting BCG-primed responses with a subunit Apa vaccine during the waning phase improves immunity and imparts protection against Mycobacterium tuberculosis Subhadra Nandakumar, Centers for Disease Control
More informationBCG: Past, Present and Future. Nwora Lance Okeke, MD, MPH August 24, 2016
BCG: Past, Present and Future Nwora Lance Okeke, MD, MPH August 24, 2016 Disclosures Nothing to disclose Overview Introduction and History Current Use Effectiveness Non-vaccine uses of BCG Edmond Nocard
More informationDiagnosis of tuberculosis in children
Diagnosis of tuberculosis in children H Simon Schaaf Desmond Tutu TB Centre Department of Paediatrics and Child Health, Stellenbosch University, and Tygerberg Children s Hospital (TCH) Estimated TB incidence
More informationEstablishment of an Aerosol Challenge Model of Tuberculosis in Rhesus Macaques and an Evaluation of Endpoints for Vaccine Testing
CLINICAL AND VACCINE IMMUNOLOGY, Aug. 2010, p. 1170 1182 Vol. 17, No. 8 1556-6811/10/$12.00 doi:10.1128/cvi.00079-10 Copyright 2010, American Society for Microbiology. All Rights Reserved. Establishment
More informationLatent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016
Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016 Randy Culpepper, MD, MPH Deputy Heath Officer/Medical Director Frederick County Health Department March 16, 2016 2 No
More informationMaking the Diagnosis of Tuberculosis
Making the Diagnosis of Tuberculosis Alfred Lardizabal, MD NJMS Global Tuberculosis Institute Testing for TB Infection Targeted Testing: Key Points Test only if plan for ensuring treatment De-emphasizes
More informationImmunology of TB and its relevance to TB Control
Immunology of TB and its relevance to TB Control W. Henry Boom, M.D. TB Research Unit Case Western Reserve University NIAID-DMID: -AI70022 Global TB Epidemiology 2009 < 10 10 to 24 25 to 49 50 to 99 100
More informationTherapeutic TB vaccines Shortening Treatment for (DS- and) DR-TB?
Therapeutic TB vaccines Shortening Treatment for (DS- and) DR-TB? Mark Hatherill South African Tuberculosis Vaccine Initiative (SATVI) University of Cape Town, South Africa 1 1. The need for a therapeutic
More informationPerspectives on Clinical and Preclinical Testing of New Tuberculosis Vaccines
CLINICAL MICROBIOLOGY REVIEWS, Oct. 2010, p. 781 794 Vol. 23, No. 4 0893-8512/10/$12.00 doi:10.1128/cmr.00005-10 Copyright 2010, American Society for Microbiology. All Rights Reserved. Perspectives on
More informationNguyen Van Hung (NTP, Viet Nam)
Technical Consultation Meeting on the Programmatic Management of Latent Tuberculosis Infection 31 August-1 September 2017, Seoul, Republic Korea Adopting new LTBI diagnostics at country level: perspective
More informationNew tools for control of bovine tuberculosis in cattle
New tools for control of bovine tuberculosis in cattle Bryce Buddle AgResearch, Hopkirk Research Institute Bovine tuberculosis (TB) in New Zealand Total cost of $100 million/year ($81 million TBfree NZ)
More informationMedical Bacteriology- lecture 13. Mycobacterium Actinomycetes
Medical Bacteriology- lecture 13 Mycobacterium Actinomycetes Mycobacterium tuberculosis Large, very weakly gram positive rods, Obligate aerobes, related to Actinomycetes, non spore forming, non motile
More informationApplication of New Diagnostics and Preventative Treatment in Low and High Burden Settings
Application of New Diagnostics and Preventative Treatment in Low and High Burden Settings Edward Nardell, MD Brigham & Women s Hospital Harvard Medical School Partners In Health Disclosures opps! Served
More informationReceived 3 August 2011/Returned for modification 22 August 2011/Accepted 28 September 2011
CLINICAL AND VACCINE IMMUNOLOGY, Dec. 2011, p. 2154 2160 Vol. 18, No. 12 1556-6811/11/$12.00 doi:10.1128/cvi.05329-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Serum Antibody
More informationTUBERCULOSIS. Pathogenesis and Transmission
TUBERCULOSIS Pathogenesis and Transmission TUBERCULOSIS Pathogenesis and Transmission Infection to Disease Diagnostic & Isolation Updates Treatment Updates Pathogenesis Droplet nuclei of 5µm or less are
More informationLouis Joslyn Dept of Bioinformatics With Dr. Denise Kirschner and Dr. Jennifer Linderman
Immunology of TB: insights from in vivo models and implications for prevention Louis Joslyn Dept of Bioinformatics With Dr. Denise Kirschner and Dr. Jennifer Linderman Dendritic cell (DC) DC responds to
More informationDidactic Series. Latent TB Infection in HIV Infection
Didactic Series Latent TB Infection in HIV Infection Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director, SF and North Coast AETC March 13, 2014 ACCREDITATION STATEMENT:
More informationExperiment #1 TARGET Mouse Model Group. Report prepared by Paul Converse, Ph.D. and Eric Nuermberger, M.D. March 1, 2006
Protocol for in vivo evaluation of growth rates and pathogenesis of M. tuberculosis strains found to have rapid or slow growth phenotypes in an in vitro model Experiment #1 TARGET Mouse Model Group Report
More informationTesting for TB. Bart Van Berckelaer Territory Manager Benelux. Subtitle
Testing for TB Bart Van Berckelaer Territory Manager Benelux Subtitle Agenda TB infection pathway TB immunisation Testing options Pre lab considerations of the whole blood ELISA test The T-SPOT.TB test
More informationTB Prevention Who and How to Screen
TB Prevention Who and How to Screen 4.8.07. IUATLD 1st Asia Pacific Region Conference 2007 Dr Cynthia Chee Dept of Respiratory Medicine / TB Control Unit Tan Tock Seng Hospital, Singapore Cycle of Infection
More informationMedical Bacteriology- Lecture 10. Mycobacterium. Actinomycetes. Nocardia
Medical Bacteriology- Lecture 10 Mycobacterium Actinomycetes Nocardia 1 Mycobacterium Characteristics - Large, very weakly gram positive rods - Obligate aerobes, related to Actinomycetes - Catalase positive
More information#4 (Tuberculosis OR TB OR Pulmonary Tuberculosis OR Multi-Drug Resistant Tuberculosis OR MDR OR Extremely-Drug Resistant Tuberculosis or XDR)
DATABASE Cochrane Database of Systematic Reviews DATE 15 DECEMBER 2015 #1 Safety of Crucell Ad35/ AERAS-402 OR Effectiveness of Crucell Ad35/ Aeras-402 OR Safety of MVA85A/ Aeras-485 OR Effectiveness of
More informationTechnical Bulletin No. 172
CPAL Central Pennsylvania Alliance Laboratory QuantiFERON -TB Gold Plus Assay Contact: J Matthew Groeller, MPA(HCM), MT(ASCP), 717-851-4516 Operations Manager, Clinical Pathology, CPAL Jennifer Thebo,
More informationFundamentals of Tuberculosis (TB)
TB in the United States Fundamentals of Tuberculosis (TB) From 1953 to 1984, reported cases decreased by approximately 5.6% each year From 1985 to 1992, reported cases increased by 20% 25,313 cases reported
More informationWHO Preferred Product Characteristics for New Tuberculosis Vaccines. World Health Organization 2017
1 2 3 4 5 6 7 8 WHO Product Characteristics for New Tuberculosis Vaccines 9 10 11 12 13 14 15 16 17 18 19 20 21 World Health Organization 2017 1 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40
More informationSelf-Study Modules on Tuberculosis
Self-Study Modules on Tuberculosis Targe te d Te s ting and the Diagnosis of Latent Tuberculosis Infection and Tuberculosis Disease U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control
More informationMonica Manandhar. 2 ND YEAR RESEARCH ELECTIVE RESIDENT S JOURNAL Volume V, A. Study Purpose and Rationale
Randomized Trial of lsoniazid as Secondary Prophylaxis for Prevention of Recurrent Pulmonary Tuberculosis in HIV-positive Patients After One Episode of Tuberculosis Monica Manandhar A. Study Purpose and
More informationSupplementary Figure 1
Supplementary Figure 1 FMO control (no HLA-DR antibody) FMO control (no HLA-DR antibody) Supplementary Figure 1. Gating strategy for HLA-DR+ T-cells. A gate was drawn around lymphocytes based on cell size
More informationTuberculosis Tools: A Clinical Update
Tuberculosis Tools: A Clinical Update CAPA Conference 2014 JoAnn Deasy, PA-C. MPH, DFAAPA jadeasy@sbcglobal.net Adjunct Faculty Touro PA Program Learning Objectives Outline the pathogenesis of active pulmonary
More informationA Clinician s Perspective: Improving Rheumatology Patient Care Using the T-SPOT.TB Test
A Clinician s Perspective: Improving Rheumatology Patient Care Using the T-SPOT.TB Test Solomon Forouzesh, MD, FACD, FACR Medical Director Arthritis Care & Treatment Center Clinical Associate Professor
More informationTuberculosis Update. Topics to be Addressed
Tuberculosis Update Robert M. Jasmer, M.D. University of California, San Francisco TB Control Section, San Francisco Department of Public Health Topics to be Addressed TB in the USA Screening recommendations
More informationTB Clinical Guidelines: Revision Highlights March 2014
TB Clinical Guidelines: Revision Highlights March 2014 AIR TRAVEL & TB CONTROL With respect to non-ambulance air travel of patients diagnosed with or suspected as having active Mycobacterium tuberculosis,
More informationPREVENTION OF TUBERCULOSIS. Dr Amitesh Aggarwal
PREVENTION OF TUBERCULOSIS Dr Amitesh Aggarwal 25 to 50 % of persons exposed to intimate contact with active PTB - latent infection with TB. Exposure to index case for 12 hours - high risk of infection.
More informationAPPLICATION OF IMMUNO CHROMATOGRAPHIC METHODS IN PLEURAL TUBERCULOSIS
APPLICATION OF IMMUNO CHROMATOGRAPHIC METHODS IN PLEURAL TUBERCULOSIS Hadizadeh Tasbiti.AR, Yari.SH, Bahrmand.AR, Karimi.A,Fateh.A, Sayfi.M Tuberculosis Dept.Pasteur Institute of Iran.Tehran.Iran 1 INTRODUCTION
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,900 116,000 120M Open access books available International authors and editors Downloads Our
More informationTB Vaccine Research and Development: Progress, Strategies and Controversies
15 March 2016 GVIRF Global Forum Johannesburg, South Africa TB Vaccine Research and Development: Progress, Strategies and Controversies Lewis Schrager, M.D. V.P., Scientific Affairs Rockville, MD USA Source:
More informationEffect of oral exposure of Mycobacterium avium intracellular on the protective immunity induced by BCG
J. Biosci., Vol. 10, Number 4, December 1986, pp. 453-460. Printed in India. Effect of oral exposure of Mycobacterium avium intracellular on the protective immunity induced by BCG SUJATHA NARAYANAN, C.
More informationIn our paper, we suggest that tuberculosis and sarcoidosis are two ends of the same spectrum. Given the pathophysiological and clinical link between
In our paper, we suggest that tuberculosis and sarcoidosis are two ends of the same spectrum. Given the pathophysiological and clinical link between the two, we also propose a classification system for
More informationResearch in Tuberculosis: Translation into Practice
Case History Research in Tuberculosis: Translation into Practice This is a 6-year6 year-old Bosnian male, who presented to ER with one-week history of fever and occasional vomiting. No cough, difficulty
More informationWHO Preferred Product Characteristics for New Tuberculosis Vaccines DEPARTMENT OF IMMUNIZATION, VACCINES AND BIOLOGICALS WHO/IVB/18.
WHO/IVB/18.06 WHO Preferred Product Characteristics for New Tuberculosis Vaccines DEPARTMENT OF IMMUNIZATION, VACCINES AND BIOLOGICALS Family, Womens s and Children s Health (FWC) This document was produced
More informationStimulation of mucosal immunity by pulmonary delivery of live vaccines. A safe and effective strategy against TB
Les Diablerets, 3rd February 2016 Stimulation of mucosal immunity by pulmonary delivery of live vaccines. A safe and effective strategy against TB Nacho Aguilo (naguilo@unizar.es) Live TB Vaccine TB infection
More informationTB 2015 burden, challenges, response. Dr Mario RAVIGLIONE Director
TB 2015 burden, challenges, response Dr Mario RAVIGLIONE Director Addis Ababa, Ethiopia 11-13 November 2015 Overview TB basics TB burden & challenges Response: End TB Strategy DAY 1 What is TB? Definition
More informationMycobacterium tuberculosis. Lecture (14) Dr.Baha, AL-Amiedi Ph. D.Microbiology
Mycobacterium tuberculosis Lecture (14) Dr.Baha, AL-Amiedi Ph. D.Microbiology Robert Koch 1843-1910 German physician Became famous for isolating the anthrax bacillus (1877), tuberculosis bacillus (1882)
More informationTargeted Testing and the Diagnosis of. Latent Tuberculosis. Infection and Tuberculosis Disease
Self-Study Study Modules on Tuberculosis Targeted Testing and the Diagnosis of Latent Tuberculosis Infection and Tuberculosis Disease 1 Module 3: Objectives At completion of this module, learners will
More informationUsing Interferon Gamma Release Assays for Diagnosis of TB Infection
Learning Objectives Using Interferon Gamma Release Assays for Diagnosis of TB Infection 1. Describe available Interferon Gamma Release Assay tests for TB infection and how they work. 2. Understand interpretation
More informationUnderstanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010
Understanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010 What is Latent TB Infection (LTBI)? Traci Hadley, RN October 5, 2010 LTBI or TB Disease? Presented by : Traci Hadley, RN
More informationCUSOM Student Health Immunization Requirements
CUSOM Student Health Immunization Requirements Regulatory and legislative authorities require that students demonstrate immunization, immunity and/or protection from multiple contagious diseases before
More informationTuberculosis Populations at Risk
Tuberculosis Populations at Risk One-third of the world is infected with TB, an average of one new infection per second Two million people died from tuberculosis in 2010, 1 every 20 seconds TB is the leading
More informationTB, BCG and other things. Chris Conlon Infectious Diseases Oxford
TB, BCG and other things Chris Conlon Infectious Diseases Oxford Epidemiology Latent TB IGRA BCG >50/100000
More informationNAAT in the Clinical Laboratory and Impact on Infection Control 9 th National Conference on Laboratory Aspects of Tuberculosis APHL
NAAT in the Clinical Laboratory and Impact on Infection Control 9 th National Conference on Laboratory Aspects of Tuberculosis APHL Susan Novak-Weekley, S(M), ASCP, Ph.D., D(ABMM) Director of Microbiology,
More informationDiagnostic Value of Elisa Serological Tests in Childhood Tuberculosis
Diagnostic Value of Elisa Serological Tests in Childhood Tuberculosis by R. Dayal, a G. Sirohi, a M. K. Singh, a P. P. Mathur, a B. M. Agarwal, a V. M. Katoch, b B. Joshi, b P. Singh, b and H. B. Singh
More informationBarbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and Infectious Disease UT Health Northeast
Practical Aspects for Using the Interferon Gamma Release Assay (IGRA) Test Live Webinar July 14, 2017 Barbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and
More informationThe Immunological Basis for Immunization Series
The Immunological Basis for Immunization Series Module 5: Tuberculosis Immunization, Vaccines and Biologicals The Immunological Basis for Immunization Series Module 5: Tuberculosis Immunization, Vaccines
More information2016 OPAM Mid-Year Educational Conference, Sponsored by AOCOPM Sunday, March 13, 2016
Learning Objectives Tuberculosis Case Discussions: Evaluation for Tuberculosis Infection Melissa C. Overman, DO, MPH, CHES, FAOCOPM Describe appropriate technique for TST placement, reading and interpretation
More informationGOVX-B11: A Clade B HIV Vaccine for the Developed World
GeoVax Labs, Inc. 19 Lake Park Drive Suite 3 Atlanta, GA 3 (678) 384-72 GOVX-B11: A Clade B HIV Vaccine for the Developed World Executive summary: GOVX-B11 is a Clade B HIV vaccine targeted for use in
More informationTB Intensive San Antonio, Texas December 1-3, 2010
TB Intensive San Antonio, Texas December 1-3, 2010 TB Pathogenesis and Transmission Lynn Horvath, MD; TCID December 1, 2010 Tuberculosis Pathogenesis Lynn L. Horvath, MD, FACP, FIDSA Associate Professor
More informationCHAPTER:1 TUBERCULOSIS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY
CHAPTER:1 TUBERCULOSIS BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY GLOBAL EMERGENCY: * Tuberculosis kills 5,000 people a day! * 2.3 million die each year!
More informationESCMID Online Lecture Library. by author
Tuberculosis prevention in immunodepressed patients M. Carmen Fariñas Álvarez Infectious Diseases.H.U.Marqués de Valdecilla University of Cantabria, Spain DISCLOSURES I have no potential conflicts with
More information2016 Annual Tuberculosis Report For Fresno County
206 Annual Tuberculosis Report For Fresno County Cases Rate per 00,000 people 206 Tuberculosis Annual Report Fresno County Department of Public Health (FCDPH) Tuberculosis Control Program Tuberculosis
More informationDidactic Series. Latent TB Infection in HIV Infection
Didactic Series Latent TB Infection in HIV Infection Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director SF, North Coast and East Bay AETC January 8, 2015 ACCREDITATION
More informationNew Entrant Screening and Latent TB Get screened and find out if you have TB infection before you develop TB disease!
New Entrant Screening and Latent TB Get screened and find out if you have TB infection before you develop TB disease! Screening and treatment for TB are free. What does this leaflet cover? What is Tuberculosis
More informationCommon things are common, but not always the answer
Kevin Conroy, Joe Mackenzie, Stephen Cowie kevin.conroy@nhs.net Respiratory Dept, Darlington Memorial Hospital, Darlington, UK. Common things are common, but not always the answer Case report Cite as:
More informationMINIREVIEW. HIV-1/Mycobacterium tuberculosis Coinfection Immunology: How Does HIV-1 Exacerbate Tuberculosis? Collin R. Diedrich and JoAnne L.
INFECTION AND IMMUNITY, Apr. 2011, p. 1407 1417 Vol. 79, No. 4 0019-9567/11/$12.00 doi:10.1128/iai.01126-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. MINIREVIEW HIV-1/Mycobacterium
More informationRespiratory System الفريق الطبي االكاديمي
Respiratory System الفريق الطبي االكاديمي Pathology sheet 5 Tuberculosis Done by: Ahmad Al-Sahele Introduction: as we know TB is caused by mycobacterium tubercolosis; now keep in your mind another microorganism
More informationCellular Immunity in Aging and HIV: Correlates of Protection. Immune Senescence
Cellular Immunity in Aging and HIV: Correlates of Protection Janet E. McElhaney, MD Professor of Medicine Allan M. McGavin Chair in Research Geriatrics University of British Columbia Vancouver, BC and
More informationPatterns of cytokine response in bcg vaccinated and BCG non-vaccinated children in the age group of 5-8 years in Chennai
Available online at www.scholarsresearchlibrary.com Central European Journal of Experimental Biology, 2012, 1 (4):134-141 (http://scholarsresearchlibrary.com/archive.html) ISSN: 2278 7364 Patterns of cytokine
More informationElucidating the Role of the Humoral Response in Mycobacterium tuberculosis infected Cynomolgus Macaques. Jia Yao Phuah
Elucidating the Role of the Humoral Response in Mycobacterium tuberculosis infected Cynomolgus Macaques by Jia Yao Phuah B.A.(Hons) M.A. (Cantab), Natural Sciences (Biochemisty), Magdalene College, University
More informationThe evolving concept of LTBI diagnosis tests for incipient TB and tests for persistent infection
The evolving concept of LTBI diagnosis tests for incipient TB and tests for persistent infection Frank Cobelens f.cobelens@aighd.org KNCV Tuberculosis Foundation The Hague, Netherlands Amsterdam Institute
More information